Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

The selective BRAF inhibitors, vemurafenib and dabrafenib, yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma. Acquired drug resistance and drug toxicity are key challenges when using these drugs. We investigated whether vemurafenib toxicit...

Full description

Bibliographic Details
Main Authors:	Andrew J. Dooley, Avinash Gupta, Madhumita Bhattacharyya, Mark R. Middleton
Format:	Article
Language:	English
Published:	SAGE Publishing 2014-11-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758834014548187

Similar Items

Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement
by: Xiaomeng Wang, et al.
Published: (2023-08-01)

Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets
by: József Tóvári, et al.
Published: (2023-07-01)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
by: Francesca Del Bufalo, et al.
Published: (2018-11-01)

Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
by: Andliena Tahiri, et al.
Published: (2013-01-01)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
by: Matthias Lang, et al.
Published: (2023-03-01)

Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf<sup>V600E</sup> Melanoma
by: Laurie Signetti, et al.
Published: (2020-06-01)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
by: Joseph I. Clark, et al.
Published: (2018-07-01)

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling
by: Yufan Tan, et al.
Published: (2021-06-01)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
by: Alessandro Nepote, et al.
Published: (2022-02-01)

Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
by: Siraj M. Ali, et al.
Published: (2014-05-01)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
by: Blessie Elizabeth Nelson, et al.
Published: (2023-02-01)

VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer
by: Shitu Chen, et al.
Published: (2020-02-01)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
by: Carlotta Guzzetti, et al.
Published: (2023-09-01)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
by: Fedor V. Moiseyenko, et al.
Published: (2019-05-01)

Efficacy and Safety of Vemurafenib in Acral and Mucosal Melanoma Patients with BRAF Gene Mutation
by: WEI Xiaoting, et al.
Published: (2018-11-01)

Acquired and intrinsic resistance to vemurafenib in BRAFV600E‐driven melanoma brain metastases
by: Ping Zhang, et al.
Published: (2024-01-01)

EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF<sup>V600E</sup> Mutated Parent- and Vemurafenib-Resistant Melanoma
by: Yige Fu, et al.
Published: (2019-10-01)

Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.
by: Fernando Lopez-Rios, et al.
Published: (2013-01-01)

HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF<sup>V600E</sup> Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
by: Anna Lisa Furfaro, et al.
Published: (2022-06-01)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
by: Ester Simeone, et al.
Published: (2021-01-01)

Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib
by: Petra Grbčić, et al.
Published: (2021-06-01)

Combination of the natural product mensacarcin with vemurafenib (Zelboraf) combats BRAF mutant and chemo-resistant melanoma in vitro by affecting cell metabolism and cellular migration
by: Elizabeth N. Kaweesa, et al.
Published: (2022-12-01)

Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib
by: Gavric Ana Ursula, et al.
Published: (2018-01-01)

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
by: Coralie Reger de Moura, et al.
Published: (2020-02-01)

Tracking of Glycans Structure and Metallomics Profiles in <i>BRAF</i> Mutated Melanoma Cells Treated with Vemurafenib
by: Monika K. Nisiewicz, et al.
Published: (2021-01-01)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
by: Muna Al Hashmi, et al.
Published: (2020-05-01)

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting
by: Molly J. Carroll, et al.
Published: (2019-10-01)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
by: Teresa Żołek, et al.
Published: (2023-07-01)

BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT
by: Ivana Inić, et al.
Published: (2014-09-01)

Amelanotic primary dermal melanoma with V600E BRAF mutation
by: Miho Kabuto, et al.
Published: (2017-06-01)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
by: Tiziana Notarangelo, et al.
Published: (2017-10-01)

Current Advances in the Treatment of BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2020-02-01)

Improvement of Neurodegenerative Disease after Use of Vemurafenib in Refractory BRAF V600E-Mutated Langerhans Cell Histiocytosis: A Case Report
by: Young Kwon Koh, et al.
Published: (2022-10-01)

Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature
by: Louis Garnier, et al.
Published: (2019-03-01)

<i>BRAF<sup>V600E</sup></i> Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics
by: Xavier Soria, et al.
Published: (2021-10-01)

Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis
by: Ling Hong, et al.
Published: (2022-04-01)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAFV600E-Mutant CRC: A Case Report and Review
by: Su Min Cho, et al.
Published: (2021-12-01)

miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.
by: Tomasz M Grzywa, et al.
Published: (2020-01-01)